GADD45G: A Potential Drug Target for Alzheimer's and Hypertension

Target Name: GADD45G

NCBI ID: G10912

GADD45G

GADD45G: A Potential Drug Target for Alzheimer's and Hypertension

GADD45G (GRP17) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a crucial role in cellular signaling. GADD45G has been identified as a potential drug target (or biomarker) due to its unique structure and the involvement of several diseases, including Alzheimer's disease and hypertension.

GADD45G was first identified in the 1990s as a gene that was expressed in the brain and other tissues. The gene is located on chromosome 12q34 and has a length of approximately 2000 amino acids. GADD45G is a protein that is made up of several domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the protein's ability to interact with other cells and tissues, while the transmembrane domain is responsible for the protein's ability to span the cell membrane and interact with intracellular signaling molecules. The intracellular domain is responsible for the protein's ability to interact with various intracellular signaling pathways, including the signaling pathways that are involved in memory and cognitive function.

One of the key features of GADD45G is its ability to interact with several different signaling pathways. For example, GADD45G has been shown to interact with the neurotransmitter receptor, N-methyl-D-aspartate (NMDA), which is involved in pain perception and neurotransmission. Additionally, GADD45G has been shown to interact with the protein p21, which is involved in the regulation of cell growth and apoptosis. GADD45G has also been shown to interact with the protein PDGF-尾, which is involved in cell signaling and growth.

GADD45G has been shown to be involved in several diseases, including Alzheimer's disease and hypertension. Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the progressive loss of brain cells. It is estimated that over 50 million people in the United States will have Alzheimer's disease by the year 2038, making it one of the most significant public health challenges of the 21st century. GADD45G has been shown to be involved in the development and progression of Alzheimer's disease, as well as in the regulation of neurotransmission.

Hypertension, or high blood pressure, is a common condition that is associated with several health problems, including heart disease, stroke, and kidney failure. It is estimated that over 1 billion people in the United States have hypertension, and it is a leading cause of death in the United States. GADD45G has been shown to be involved in the regulation of blood pressure, as well as in the development and progression of hypertension.

In conclusion, GADD45G is a protein that has been identified as a potential drug target (or biomarker) due to its unique structure and the involvement of several diseases, including Alzheimer's disease and hypertension. Further research is needed to fully understand the role of GADD45G in these diseases and to develop effective treatments.

Protein Name: Growth Arrest And DNA Damage Inducible Gamma

Functions: Involved in the regulation of growth and apoptosis. Mediates activation of stress-responsive MTK1/MEKK4 MAPKKK

The "GADD45G Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GADD45G comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets